Ian S. Fentiman

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

Nina Bijker, Philip Meijnen, Johannes L. Peterse et al. · Journal of Clinical Oncology · 2006 · 657 citations

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

Jack Cuzick, Ivana Šestak, Sarah E. Pinder et al. · The Lancet Oncology · 2010 · 564 citations · Full text

Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial

Saskia Litière, Gustavo Werutsky, Ian S. Fentiman et al. · The Lancet Oncology · 2012 · 543 citations

Surgical Oncology, Breast Oncology, Medicine +8

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853

Jean‐Pierre Julien, Nina Bijker, Ian S. Fentiman et al. · The Lancet · 2000 · 510 citations

Surgical Oncology, Radiation Therapy, Medicine +10

Risk Factors for Recurrence and Metastasis After Breast-Conserving Therapy for Ductal Carcinoma-In-Situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853

Nina Bijker, Johannes L. Peterse, Luc Duchateau et al. · Journal of Clinical Oncology · 2001 · 497 citations